Asia Pacific Inhalation Anesthesia Market Size & Outlook
Asia Pacific inhalation anesthesia market, 2018-2030 (US$M)
Related Markets
Asia Pacific inhalation anesthesia market highlights
- The Asia Pacific inhalation anesthesia market generated a revenue of USD 195.5 million in 2022.
- The market is expected to grow at a CAGR of 9.7% from 2023 to 2030.
- In terms of segment, sevoflurane was the largest revenue generating drug in 2022.
- Isoflurane is the most lucrative drug segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2023 to 2030.
Asia Pacific data book summary
| Market revenue in 2022 | USD 195.5 million |
| Market revenue in 2030 | USD 411.1 million |
| Growth rate | 9.7% (CAGR from 2022 to 2030) |
| Largest segment | Sevoflurane |
| Fastest growing segment | Isoflurane |
| Historical data covered | 2016 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Sevoflurane, Desflurane, Isoflurane, Halothane |
| Key market players worldwide | Baxter International Inc, AbbVie Inc, Fresenius SE & Co KGaA, Sandoz Group AG ADR, Piramal Enterprises, Halocarbon Products Corporation, Lunan Pharmaceutical Group |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 16.1% of the global inhalation anesthesia market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 411.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Inhalation Anesthesia Market Scope
Inhalation Anesthesia Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific inhalation anesthesia market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to inhalation anesthesia market will help companies and investors design strategic landscapes.
Sevoflurane was the largest segment with a revenue share of 62.81% in 2024. Horizon Databook has segmented the Asia Pacific inhalation anesthesia market based on sevoflurane, desflurane, isoflurane, halothane covering the revenue growth of each sub-segment from 2018 to 2030.
The inhalation anesthesia market in the Asia Pacific is witnessing robust growth, driven by demographic changes, particularly the aging population and increased life expectancy, leading to a higher incidence of chronic diseases that necessitate surgical interventions.
Furthermore, lifestyle factors, such as sedentary behavior and poor dietary choices, contribute to the prevalence of conditions like obesity, diabetes, and cardiovascular diseases, which frequently require surgical treatment.
Reasons to subscribe to Asia Pacific inhalation anesthesia market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific inhalation anesthesia market databook
-
Our clientele includes a mix of inhalation anesthesia market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific inhalation anesthesia market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific inhalation anesthesia market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific inhalation anesthesia market size, by country, 2018-2030 (US$M)
Asia Pacific Inhalation Anesthesia Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
